These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36564186)

  • 21. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
    Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
    JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in HIV post-exposure prophylaxis following sexual exposure in Brazil (2011-2019).
    Crepalde-Ribeiro K; de Oliveira Costa J; Pearson SA; Silveira MR; Mendes JC; Dos Santos SF; Cruz MA; Braga MDG
    AIDS Behav; 2022 Dec; 26(12):4115-4125. PubMed ID: 35841464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study.
    Hoornenborg E; Coyer L; Achterbergh RCA; Matser A; Schim van der Loeff MF; Boyd A; van Duijnhoven YTHP; Bruisten S; Oostvogel P; Davidovich U; Hogewoning A; Prins M; de Vries HJC;
    Lancet HIV; 2019 Jul; 6(7):e447-e455. PubMed ID: 31178284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sexual behaviour and incidence of sexually transmitted infections among men who have sex with men (MSM) using daily and event-driven pre-exposure prophylaxis (PrEP): Four-year follow-up of the Amsterdam PrEP (AMPrEP) demonstration project cohort.
    van den Elshout MAM; Wijstma ES; Boyd A; Jongen VW; Coyer L; Anderson PL; Davidovich U; de Vries HJC; Prins M; Schim van der Loeff MF; Hoornenborg E;
    PLoS Med; 2024 May; 21(5):e1004328. PubMed ID: 38718068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence.
    Vuylsteke B; Reyniers T; De Baetselier I; Nöstlinger C; Crucitti T; Buyze J; Kenyon C; Wouters K; Laga M
    J Int AIDS Soc; 2019 Oct; 22(10):e25407. PubMed ID: 31663257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
    Mayer KH; Yuhas K; Amico KR; Wilkin T; Landovitz RJ; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Cottle LM; Marcus C; Chege W; Rinehart AR; Rooney JF; Andrew P; Salata RA; Magnus M; Farley JE; Liu AY; Frank I; Ho K; Santana J; Stekler JD; Chen YQ; McCauley M; Gulick RM;
    AIDS Behav; 2022 Dec; 26(12):4107-4114. PubMed ID: 35687192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised controlled trial of a telephone administered brief HIV risk reduction intervention amongst men who have sex with men prescribed post-exposure prophylaxis for HIV after sexual exposure in the UK: Project PEPSE.
    Llewellyn CD; Abraham C; Pollard A; Jones CI; Bremner S; Miners A; Smith H
    PLoS One; 2019; 14(5):e0216855. PubMed ID: 31120898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
    Hoagland B; Moreira RI; De Boni RB; Kallas EG; Madruga JV; Vasconcelos R; Goulart S; Torres TS; Marins LMS; Anderson PL; Luz PM; Costa Leite ID; Liu AY; Veloso VG; Grinsztejn B;
    J Int AIDS Soc; 2017 Apr; 20(1):21472. PubMed ID: 28418232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
    Blair HA
    Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of Kenyan women using HIV PrEP enrolled in a randomized trial on doxycycline postexposure prophylaxis for sexually transmitted infection prevention.
    Oware K; Adiema L; Rono B; Violette LR; McClelland RS; Donnell D; Scoville CW; Odoyo J; Baeten JM; Bukusi E; Stewart J
    BMC Womens Health; 2023 Jun; 23(1):296. PubMed ID: 37270546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin.
    Ahouada C; Diabaté S; Mondor M; Hessou S; Guédou FA; Béhanzin L; Batona G; Gning NN; Zannou DM; Alary M
    BMC Public Health; 2020 Aug; 20(1):1267. PubMed ID: 32819335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo.
    Mizushima D; Takano M; Ando N; Uemura H; Yanagawa Y; Aoki T; Watanabe K; Ishizuka N; Oka S
    J Infect Chemother; 2022 Jun; 28(6):762-766. PubMed ID: 35248496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.
    Laurent C; Dembélé Keita B; Yaya I; Le Guicher G; Sagaon-Teyssier L; Agboyibor MK; Coulibaly A; Traoré I; Malan JB; De Baetselier I; Eubanks A; Riegel L; Rojas Castro D; Fayé-Ketté H; Koné A; Diandé S; Dagnra CA; Serrano L; Diallo F; Mensah E; Dah TTE; Anoma C; Vuylsteke B; Spire B;
    Lancet HIV; 2021 Jul; 8(7):e420-e428. PubMed ID: 34048794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
    Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
    Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
    Noret M; Balavoine S; Pintado C; Siguier M; Brun A; Bauer R; Loze B; Leplatois A; Aslan A; Moudachirou K; Delaugerre C; Rozenbaum W; Molina JM
    AIDS; 2018 Sep; 32(15):2161-2169. PubMed ID: 30212403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.
    Petruccelli KCS; Baía-da-Silva DC; Val F; Valões MS; Cubas-Vega N; Silva-Neto AV; Sampaio V; Alencar A; Pecoits-Filho R; Moreira RC; Cardoso SW; Moreira RI; Leite IC; Madruga JV; Kallas EG; Alencastro PR; Hoagland B; Grinsztejn B; Santos VGV; Lacerda MVG
    AIDS Res Ther; 2022 Feb; 19(1):12. PubMed ID: 35209929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sexually transmitted infections incidence in young Thai men who have sex with men and transgender women using HIV pre-exposure prophylaxis.
    Songtaweesin WN; Pornpaisalsakul K; Kawichai S; Wacharachaisurapol N; Wongharn P; Yodkitudomying C; Panichnantakul P; Theerawit T; Pankam T; Puthanakit T
    Int J STD AIDS; 2022 Apr; 33(5):447-455. PubMed ID: 35282719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
    Liu AY; Cohen SE; Vittinghoff E; Anderson PL; Doblecki-Lewis S; Bacon O; Chege W; Postle BS; Matheson T; Amico KR; Liegler T; Rawlings MK; Trainor N; Blue RW; Estrada Y; Coleman ME; Cardenas G; Feaster DJ; Grant R; Philip SS; Elion R; Buchbinder S; Kolber MA
    JAMA Intern Med; 2016 Jan; 176(1):75-84. PubMed ID: 26571482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
    Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
    Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.